PD173074

Licensed by Pfizer Catalog No.S1264

PD173074 Chemical Structure

Molecular Weight(MW): 523.67

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Size Price Stock Quantity  
In DMSO USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331(6019), 912-6. PD173074 purchased from Selleck.

    Inhibition of FGFR signaling pathway by FGFR inhibitor PD173074 in mouse xenograft tumors. Bladder cancer SW780 cells were implanted in mice and treated with PD173074 after tumor formation as shown in B. Protein lysates of tumor tissues were prepared and immunoblotted with antibodies against phospho-ERK1/2, pan-ERK1/2, and γ-tubulin.

    Cancer Discov 2013 3(6), 636-47. PD173074 purchased from Selleck.

  • FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.

    Hepatology 2014 59(4) ,1427-34. PD173074 purchased from Selleck.

    The level of p-FRS2 was examined in the uterine sections of Msx1f/fMsx2f/f (upper panel) and Msx1d/dMsx2d/d (lower panel) mice on day 4 of pregnancy by immunohistochemistry. Magnification: a and d: 10 x, b and e: 20 x, c and f: 40x. FGFR-specific inhibitor PD173074 was applied to one uterine horn of Msx1d/dMsx2d/d (n = 3) mice on day 3 of pregnancy. The other horn served as vehicle-treated control. Uterine horns were collected on day 4 morning and sections were subjected to immunohistochemistry to detect p-FRS2, Ki67, and Muc-1.

    PLoS Genet 2012 8(2), e1002500. PD173074 purchased from Selleck.

  • Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 ℃ for 48 h, and the appearance of the mature protein, band C, monitored by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle- alone control, 27℃ represents temperature rescue of F508-CFTR at 27℃, 37℃ represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.

    Biochem Bioph Res Co 2012 11(9), 745-57. PD173074 purchased from Selleck.

    Cells were incubated with DMSO control, 10 uM TGFBR inhibitor or 10 uM FGFR inhibitor PD173074 for 1 h. Cells were fixed, labeled with anti-GM130 (red) and analyzed by confocal microscopy. Images were analyzed using Image J (n = 3 experiments, >100 cells per condition). Scale bars, 10 uM.

    J Cell Sci 2014 10.1242/jcs.159608. PD173074 purchased from Selleck.

  • Effects of antagonists for RAGE (FPS-ZM), TLR-4 (TAK-242) and FGFR1 (PD and BGJ) on the S100B-induced alterations in glucose metabolism in L6 cells treated for 6 h. (A) Effects of FPS-ZM, (B) TAK-242 and (C) PD and BGJ on the S100B inhibition of glucose consumption.

    Am J Physiol Endocrinol Metab, 2017. PD173074 purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
c-Src [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
~25 nM 100 nM-200 nM 19.8 μM >50 μM >50 μM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEGyNlUh|ryP M4nRV3NCVkeHUh?=
KG-1 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\YRXlyUUN3ME2wMlA2OTJ7IN88US=> NFrMfGJUSU6JRWK=
MFM-223 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW1TWM2OD1yLkKxOVc3KM7:TR?= NU\wfo5GW0GQR1XS
EoL-1-cell M{TBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwM{K5PFQh|ryP M37VfnNCVkeHUh?=
ECC10 M4\2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ToPWlEPTB;MD6zN|g6QCEQvF2= M3OzRXNCVkeHUh?=
H-EMC-SS NICyfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\CV2lEPTB;MD6zOFcyPSEQvF2= NFzjZVJUSU6JRWK=
AN3-CA MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrnbZNlUUN3ME2wMlQxOTN|IN88US=> NF\qOppUSU6JRWK=
HuO-3N1 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnZTWM2OD1yLkW0OlU{KM7:TR?= NFHR[IdUSU6JRWK=
RT-112 NH3ReFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H3UmlEPTB;MD61OFcxOSEQvF2= Mln0V2FPT0WU
NEC8 NIT4VFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fE[2lEPTB;MD61OlI5QSEQvF2= M4SxdHNCVkeHUh?=
D-263MG M4XqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu1PHlWUUN3ME2wMlcyOTV7IN88US=> MXHTRW5ITVJ?
SW962 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M371bGlEPTB;MD63PFk5QCEQvF2= NVTYbYhkW0GQR1XS
BV-173 NY\DSpF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW1e45CUUN3ME2wMlg1PjJ|IN88US=> M{PBdnNCVkeHUh?=
MFE-280 M{\6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfwXIJYUUN3ME2wMlg2QDd{IN88US=> MVXTRW5ITVJ?
HuH-7 M3WwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG1TWM2OD1zLkK0OFY1KM7:TR?= MV7TRW5ITVJ?
RS4-11 NYXURmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zEWmlEPTB;MT6zN|g5PiEQvF2= M{Ti[HNCVkeHUh?=
DMS-114 M1;DbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTxNGxCUUN3ME2xMlM3PzN5IN88US=> M3vUUHNCVkeHUh?=
MSTO-211H NYTQeFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwNEezO|gh|ryP M4DyVXNCVkeHUh?=
DU-145 NF20bYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwNUiyNVch|ryP MmLQV2FPT0WU
A172 MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorvTWM2OD1zLkewN|U2KM7:TR?= M{PEPXNCVkeHUh?=
SBC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHflSZdKSzVyPUKuNFk1KM7:TR?= MYfTRW5ITVJ?
H9 NYK0c2czT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PtWWlEPTB;Mj6xOFMxPiEQvF2= M4[xdnNCVkeHUh?=
NCI-SNU-1 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHidYEzUUN3ME2yMlE5Ozl2IN88US=> MkH5V2FPT0WU
NCI-H720 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJwMkGyPFMh|ryP M2\CZnNCVkeHUh?=
HCC2218 M3nBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmw[Ih1UUN3ME2yMlM4QTN7IN88US=> MkH0V2FPT0WU
G-401 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwNEexPFkh|ryP MnTFV2FPT0WU
MPP-89 M4KyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjCR5VPUUN3ME2yMlQ5OzZ2IN88US=> MXvTRW5ITVJ?
697 NV7SZnpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnCTWM2OD1{Lk[1N|MyKM7:TR?= MULTRW5ITVJ?
KARPAS-45 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP0e5NKSzVyPUKuO|A4PDdizszN Mmr0V2FPT0WU
MG-63 NFnCRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILpS4hKSzVyPUKuPVQzPjJizszN M2fzcnNCVkeHUh?=
NTERA-S-cl-D1 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNwMEO0O|Ih|ryP M4SyWXNCVkeHUh?=
G-402 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;WRYNKSzVyPUOuNVI4OjdizszN NE\TNoNUSU6JRWK=
NKM-1 NXqwPIE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7hb|ZKSzVyPUOuNVM2PjRizszN MXrTRW5ITVJ?
RH-18 NIPnelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n2UmlEPTB;Mz6xPVU6QCEQvF2= MnTkV2FPT0WU
NCI-H1092 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnyXllNUUN3ME2zMlE6PjlizszN M4XqZXNCVkeHUh?=
RPMI-8226 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qzcWlEPTB;Mz6yN|Q1PyEQvF2= NUfZS3FUW0GQR1XS
GAMG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnTZW5UUUN3ME2zMlQ3PTd4IN88US=> M{P6NnNCVkeHUh?=
HH MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vVNmlEPTB;Mz60O|Y4PiEQvF2= MmnBV2FPT0WU
RO82-W-1 M{LyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwNEm4OVUh|ryP MkX4V2FPT0WU
CCRF-CEM MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwNUC0PFgh|ryP Mn\SV2FPT0WU
NBsusSR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vQZWlEPTB;Mz62N|k3QSEQvF2= Ml\OV2FPT0WU
CHL-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jpWGlEPTB;Mz62OVc6QSEQvF2= MX\TRW5ITVJ?
LK-2 NHTrU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HO[GlEPTB;Mz62O|E{OyEQvF2= MYPTRW5ITVJ?
Hs-578-T NInaPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfpOY5GUUN3ME2zMlY4QDd|IN88US=> M{LUR3NCVkeHUh?=
CTB-1 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNwOECwOVEh|ryP MoG5V2FPT0WU
ES5 NV;sSJNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L4N2lEPTB;Mz64N|Y{PyEQvF2= NUW1fZY2W0GQR1XS
A204 M{P4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrkTWM2OD1|LkmyNFc2KM7:TR?= NYPSSmtvW0GQR1XS
SW780 Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG1T|I2UUN3ME2zMlkzOjR3IN88US=> M2rzenNCVkeHUh?=
EW-3 M4\6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWzbpJIUUN3ME2zMlk5QTJ|IN88US=> MUnTRW5ITVJ?
A704 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP2cJh{UUN3ME20MlI5PzJ|IN88US=> MXPTRW5ITVJ?
LU-139 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInF[HVKSzVyPUSuN|E2OzRizszN MoC0V2FPT0WU
CAL-72 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\2OFJKSzVyPUSuOFE4PDZizszN M{e0XXNCVkeHUh?=
D-336MG NEHnSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvKTWM2OD12LkS2PFE4KM7:TR?= M2m0SXNCVkeHUh?=
LAMA-84 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXIRXFKSzVyPUSuOVM{OSEQvF2= NGnocFZUSU6JRWK=
GI-ME-N MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nPUGlEPTB;ND61OFgyKM7:TR?= NFjEN5hUSU6JRWK=
KM-H2 M4HrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LEXGlEPTB;ND61OVIzOiEQvF2= NWTQVo5pW0GQR1XS
NCI-H209 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV21ZpJTUUN3ME20MlU5Ojh|IN88US=> M3HrRnNCVkeHUh?=
IGROV-1 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\U[2lEPTB;ND64O|E3QCEQvF2= MWTTRW5ITVJ?
L-363 NITEXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHBV5ZkUUN3ME20Mlk3PjZ3IN88US=> M3vJRXNCVkeHUh?=
SK-MEL-3 NUnwTm9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mxeGlEPTB;NT6yOFA3KM7:TR?= MV3TRW5ITVJ?
HuO9 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHk[JZKSzVyPUWuN|g5PDNizszN Mn7VV2FPT0WU
NOS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L2UWlEPTB;NT63NlkzPyEQvF2= Ml7KV2FPT0WU
NCI-H1770 NEe4[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jGZmlEPTB;NT65OVA{OiEQvF2= MoSxV2FPT0WU
SF126 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIntPWZKSzVyPU[uNlE1ODZizszN MnrqV2FPT0WU
ML-2 NXnSTFR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrqTFBKSzVyPU[uNlQ6PzdizszN M2HmbHNCVkeHUh?=
CHP-134 NILi[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;JTWM2OD14LkK1NVgzKM7:TR?= M1fpXHNCVkeHUh?=
NCI-H1355 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nMcGlEPTB;Nj60NVc{OyEQvF2= MUnTRW5ITVJ?
TE-12 NFi4emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTTSIFiUUN3ME22MlczPjdzIN88US=> NFLreVNUSU6JRWK=
A4-Fuk NIrKfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz0TWM2OD14LkezNVQzKM7:TR?= NWHrcm12W0GQR1XS
MV-4-11 NU\FSIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK4N2lKSzVyPU[uO|Y3OjZizszN MkPSV2FPT0WU
SK-UT-1 NF3GR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKzTlhKSzVyPU[uPVE4QDRizszN NYHZN2U5W0GQR1XS
J-RT3-T3-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjuTWM2OD15LkC3O|Y1KM7:TR?= MUHTRW5ITVJ?
ME-180 NWLmcVR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnBVll7UUN3ME23MlExPDB2IN88US=> Mn:1V2FPT0WU
SK-MEL-28 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTdwM{e4NVkh|ryP M2XWZXNCVkeHUh?=
HAL-01 NG\YSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi1S4FKSzVyPUeuOFg{PDFizszN NWPYPZpOW0GQR1XS
ES8 NIHkZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr2cGNZUUN3ME23MlY6PjJ4IN88US=> NFzYR3hUSU6JRWK=
DB MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzBS3VVUUN3ME24MlEyPTB2IN88US=> NEjFPGxUSU6JRWK=
SK-NEP-1 M1e5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq4TWM2OD16LkS4NVQ6KM7:TR?= MlfsV2FPT0WU
COR-L88 M4P3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRThwNUC5PFEh|ryP MVPTRW5ITVJ?
LB1047-RCC NYm4RpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm0WXk6UUN3ME24MlUzOjF{IN88US=> NVHDT5hqW0GQR1XS
NCI-H520 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRThwNkKxOVch|ryP NXT0XJEzW0GQR1XS
SW954 M3;YZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRThwNkm3PFYh|ryP NH2z[|RUSU6JRWK=
TE-6 M{n3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnuTmhxUUN3ME24Mlc2OTR|IN88US=> M{fhZnNCVkeHUh?=
D-283MED M3z3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvoTWM2OD17LkC2OVM1KM7:TR?= MXHTRW5ITVJ?
DBTRG-05MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTlwMEm2NFch|ryP NVLZToV7W0GQR1XS
NCI-H446 M3rkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXkPZd2UUN3ME25MlI6PTJ4IN88US=> M4\MOnNCVkeHUh?=
HOS NF22V5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPMTWM2OD17LkO1NVM1KM7:TR?= M3exN3NCVkeHUh?=
ES4 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTlwNUC1PVUh|ryP NYG3RYFpW0GQR1XS
EW-13 M1j5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTlwOEmwOVUh|ryP MYHTRW5ITVJ?
IST-MES1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTlwOUS1N|Qh|ryP M3m5XXNCVkeHUh?=
CAS-1 M3[zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjOZWFSUUN3ME25Mlk4PjV7IN88US=> NHm2bYlUSU6JRWK=
EM-2 NV7ORVBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnxNnJKSzVyPUGwMlE{QTNizszN NUDVRWZOW0GQR1XS
SW948 NIDpS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFyLkG4PFIh|ryP NEXSOpFUSU6JRWK=
OAW-42 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnM[WN[UUN3ME2xNE42OjZ5IN88US=> MYrTRW5ITVJ?
BE-13 NVmyZpZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;FN2lEPTB;MUCuOlU4PiEQvF2= M17j[HNCVkeHUh?=
KU812 NFvMUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDueFgxUUN3ME2xNE44OzlzIN88US=> MU\TRW5ITVJ?
SK-MEL-30 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFyLki5NFEh|ryP MYjTRW5ITVJ?
A2780 M4HNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jSfWlEPTB;MUGuNFMxQCEQvF2= NX3pO5Q4W0GQR1XS
TGBC24TKB NXT3UWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TmUWlEPTB;MUGuNFc{PyEQvF2= Mmn4V2FPT0WU
GOTO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17VWWlEPTB;MUGuNlA5PCEQvF2= MVHTRW5ITVJ?
NCI-H526 NYDXS2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFzLkO4N|ch|ryP NX7UTpR5W0GQR1XS
BHT-101 M2\oZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[3VlVKSzVyPUGxMlQ1PTZizszN M3OyZXNCVkeHUh?=
NCI-H1155 M{jEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX5TWM2OD1zMT60PVQ4KM7:TR?= NFTKZWVUSU6JRWK=
MCF7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPZTWM2OD1zMT62NVY4KM7:TR?= M2XrPXNCVkeHUh?=
MKN45 NEjHfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrSTWM2OD1zMT63PVk{KM7:TR?= NH;1Z3NUSU6JRWK=
MOLT-16 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG5dXl1UUN3ME2xNU46Pjl{IN88US=> NH3UO2pUSU6JRWK=
YH-13 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHINldzUUN3ME2xNk4xOzR4IN88US=> MmOxV2FPT0WU
P12-ICHIKAWA MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrXXYlpUUN3ME2xNk4{QDR3IN88US=> NULkOoZ3W0GQR1XS
GR-ST MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF{LkWyPVUh|ryP NIm4fVRUSU6JRWK=
CAKI-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n1UmlEPTB;MUKuO|kyKM7:TR?= MnzHV2FPT0WU
LXF-289 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF|LkC4N|Uh|ryP MlXBV2FPT0WU
MHH-PREB-1 M4nGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLiTWM2OD1zMz6yO|A1KM7:TR?= MV7TRW5ITVJ?
EW-16 NFW1dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0PXVZUUN3ME2xN{4{OTh5IN88US=> NF72XYFUSU6JRWK=
NCI-H82 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LWR2lEPTB;MUOuOFE6PSEQvF2= MorNV2FPT0WU
MMAC-SF MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG1VXJxUUN3ME2xN{41PTR5IN88US=> M1jVenNCVkeHUh?=
COLO-684 M4W1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnQUFYzUUN3ME2xN{42OzF6IN88US=> MmrCV2FPT0WU
QIMR-WIL M2S5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCyTWM2OD1zMz64NVA6KM7:TR?= NWXxU2hnW0GQR1XS
NB69 NYS3XopnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7QTWM2OD1zMz65PFY5KM7:TR?= NYHhdYFFW0GQR1XS
NCI-H2291 M13E[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF2LkS0OVMh|ryP Ml7KV2FPT0WU
MKN7 M{O5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3FWYxKSzVyPUG0MlY3PzZizszN M{f2SnNCVkeHUh?=
HDLM-2 NWDHW2J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TZN2lEPTB;MUWuNVI5PiEQvF2= M1e3dnNCVkeHUh?=
A253 NELtd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnOcFVKSzVyPUG1MlM5PjlizszN M37wVHNCVkeHUh?=
SK-LU-1 NFH5TJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF3LkmwPVQh|ryP M{PJO3NCVkeHUh?=
MEG-01 NXuxR|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF3LkmxNFch|ryP MlnSV2FPT0WU
SK-N-DZ NI[3eFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPNTWM2OD1zNT65N|c3KM7:TR?= NFvZc3VUSU6JRWK=
H4 M13HR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF4LkC4PEDPxE1? MV3TRW5ITVJ?
LU-65 NEXHTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qwfWlEPTB;MU[uN|M5PCEQvF2= NV3Me|JTW0GQR1XS
NCI-H1048 NYfBO25CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHIS5ZKSzVyPUG2MlUyPjVizszN NGGxXohUSU6JRWK=
LCLC-97TM1 M2\VTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m2U2lEPTB;MU[uOVg5QSEQvF2= MmC4V2FPT0WU
CAL-120 M3;EeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;LNGlEPTB;MU[uPVg4QSEQvF2= MnLqV2FPT0WU
LU-134-A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjWTWM2OD1zNz6zN|kyKM7:TR?= NWD1UZhMW0GQR1XS
SK-MEL-1 NGrnN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7re3ZKSzVyPUG3MlcyOjdizszN NEm1XYlUSU6JRWK=
NCI-H69 NU[xTJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGxTWM2OD1zNz65N|A4KM7:TR?= M3jpVnNCVkeHUh?=
MC116 NXruSmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF5Lkm3OUDPxE1? NWnHSZdjW0GQR1XS
UMC-11 NF31eWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF6LkG3PFgh|ryP Mm\LV2FPT0WU
HCC1395 NF:3fmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF6LkSzNFEh|ryP M2TpWnNCVkeHUh?=
no-10 NEDlUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\LTWM2OD1zOD62N|g5KM7:TR?= NVfXeIltW0GQR1XS
NY NFWwZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLrTWM2OD1zOT6wPFA6KM7:TR?= M2XzXXNCVkeHUh?=
OS-RC-2 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;x[nJKSzVyPUG5MlEzPTJizszN MWXTRW5ITVJ?
D-423MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\xUHNKSzVyPUG5MlM6PTJizszN NFTIOVlUSU6JRWK=
LC-2-ad MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX1NXBIUUN3ME2xPU44PjF{IN88US=> MUjTRW5ITVJ?
DU-4475 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF7Lki4OVIh|ryP NVv0dIxKW0GQR1XS
YKG-1 MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OxNGlEPTB;MUmuPVYzKM7:TR?= MoDrV2FPT0WU
HCC1569 NIi4PItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTDcIFKSzVyPUKwMlI3OjRizszN MVPTRW5ITVJ?
TYK-nu M4jndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWraNVNTUUN3ME2yNE4zQDR5IN88US=> Mn\DV2FPT0WU
DEL MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGycpByUUN3ME2yNE46QDB6IN88US=> NUPBbnMyW0GQR1XS
MHH-ES-1 NGLDTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z6e2lEPTB;MkGuN|U6PyEQvF2= NG\nZmxUSU6JRWK=
KARPAS-299 NFXUVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJzLkWyPUDPxE1? M2S2XXNCVkeHUh?=
CTV-1 NU\uV2JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG2OYVTUUN3ME2yNU43OTd{IN88US=> MmnNV2FPT0WU
NCI-H2452 M1Tm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP3[lJKSzVyPUKyMlY3PzdizszN M{ntbXNCVkeHUh?=
D-566MG M2[0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPoRW1KSzVyPUKyMlc3ODFizszN MVvTRW5ITVJ?
EFO-27 NWrFeo1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ|LkC2OVEh|ryP NXT1XmpYW0GQR1XS
NCI-H596 NUPHOW5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfkTWM2OD1{Mz64OVI4KM7:TR?= MkXvV2FPT0WU
KS-1 NIe0cY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPTTWM2OD1{ND6yO|U6KM7:TR?= MmjVV2FPT0WU
8305C MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ2LkSwOFUh|ryP M3n3V3NCVkeHUh?=
A427 M4[yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ3LkCzNlMh|ryP MYDTRW5ITVJ?
COLO-800 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG2VJNKSzVyPUK1MlExPjFizszN NHHadpZUSU6JRWK=
SJRH30 NWTWNXZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO3Rm83UUN3ME2yOU4{QTB6IN88US=> MYTTRW5ITVJ?
MEL-HO M2D3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\WUIFKSzVyPUK1MlQ{OTlizszN MkfzV2FPT0WU
FTC-133 NIHKZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTiTWM2OD1{NT64NVg3KM7:TR?= MlThV2FPT0WU
SF295 M{\RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD1{Nj6yPVYh|ryP M1[4V3NCVkeHUh?=
SW1710 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\rbWJKSzVyPUK2MlQyOjNizszN NVXre2lLW0GQR1XS
EFM-19 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrieWk4UUN3ME2yOk45OTR3IN88US=> M1nncHNCVkeHUh?=
NB10 M33semdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGwTWM2OD1{OD6yNlk4KM7:TR?= M13jNHNCVkeHUh?=
TK10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ6LkKzPVkh|ryP M4m1UHNCVkeHUh?=
D-502MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrLTWM2OD1{OD60JO69VQ>? M4C3cHNCVkeHUh?=
EW-18 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTTTWM2OD1{OD60N|g3KM7:TR?= NHz5[pRUSU6JRWK=
VMRC-RCZ NIrtb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrCV4xKSzVyPUK4Mlk1OSEQvF2= M{mwNXNCVkeHUh?=
Ca9-22 NEfQd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\yTWM2OD1{OT60OVU4KM7:TR?= MmD6V2FPT0WU
KYSE-70 NYDXN|BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rjSGlEPTB;MkmuOVc5PiEQvF2= MonMV2FPT0WU
A101D M{LNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ7Lk[0O|Ih|ryP NWDKRWtzW0GQR1XS
WM-115 NELpe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DaVmlEPTB;MkmuO|YxPyEQvF2= Ml7TV2FPT0WU
HCC2157 NHPhN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHPeldKSzVyPUK5Mlg5ODdizszN NHvaTFdUSU6JRWK=
TE-9 NF71cIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrtTWM2OD1{OT64PFY2KM7:TR?= M{TMOnNCVkeHUh?=
K-562 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNyLkC5N|Mh|ryP M33BSnNCVkeHUh?=
SN12C MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLhTlBKSzVyPUOwMlE1OjZizszN MYXTRW5ITVJ?
ESS-1 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNyLkS3OVkh|ryP MVXTRW5ITVJ?
K5 M3\UOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNyLke2OEDPxE1? M1H6R3NCVkeHUh?=
J82 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXhVGRHUUN3ME2zNU4xQDl5IN88US=> NYX1d|F2W0GQR1XS
HOP-92 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTNzLkGxNVEh|ryP NITsSmtUSU6JRWK=
NCI-H2228 NWS0No44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTSIM1UUN3ME2zNU4{Ojl4IN88US=> MXXTRW5ITVJ?
OCI-AML2 NH3SZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\hR3BoUUN3ME2zNU4{PjFizszN MmWyV2FPT0WU
NCI-SNU-5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNzLkixN|ch|ryP NG[4TopUSU6JRWK=
A3-KAW NIW3b2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ywXWlEPTB;M{GuPVI1OyEQvF2= MnXMV2FPT0WU
LCLC-103H M4jxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrFcJlKSzVyPUOyMlAyPzFizszN NFz1TVlUSU6JRWK=
KY821 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN{Lk[4PFQh|ryP MX\TRW5ITVJ?
JVM-2 Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLITWM2OD1|Mj65NFc6KM7:TR?= NXjlV2pHW0GQR1XS
Mo-T M2fDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq3S29CUUN3ME2zN{4yODB3IN88US=> NHXlfpdUSU6JRWK=
IA-LM MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN|LkK3OUDPxE1? MWLTRW5ITVJ?
C8166 NUPwUoFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HhU2lEPTB;M{OuN|E6OiEQvF2= MYTTRW5ITVJ?
TCCSUP NEfwOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DaO2lEPTB;M{OuOFMxPyEQvF2= NHHXXYtUSU6JRWK=
JEG-3 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XzO2lEPTB;M{OuOFc3QCEQvF2= M36zfnNCVkeHUh?=
MS-1 M1\QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXraXYR2UUN3ME2zN{42PTVzIN88US=> NIDZNoZUSU6JRWK=
NCI-H1304 NHzubIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN|LkW3NlUh|ryP MVXTRW5ITVJ?
Ramos-2G6-4C10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLxTWM2OD1|ND6wN|M2KM7:TR?= MorhV2FPT0WU
MDA-MB-453 NYL2fJM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2TWM2OD1|ND62N|k2KM7:TR?= M3PaWHNCVkeHUh?=
KYSE-520 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm3TWM2OD1|ND63NVgyKM7:TR?= NXvwNYRrW0GQR1XS
SW900 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrHXVhKSzVyPUO0MlgyOTVizszN MY\TRW5ITVJ?
HCC2998 NEDKT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnCUHpZUUN3ME2zOU4yPTJ7IN88US=> Ml;VV2FPT0WU
A2058 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN3Lk[wOlEh|ryP NHzUUmhUSU6JRWK=
OVCAR-3 NXzVW4hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7TNJNzUUN3ME2zOk4zODR3IN88US=> MYHTRW5ITVJ?
MOLT-4 M4\0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHpbJF4UUN3ME2zOk4zOjl2IN88US=> MmjnV2FPT0WU
CAPAN-1 MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O1WWlEPTB;M{[uOFY6QSEQvF2= M4XhfnNCVkeHUh?=
SCC-9 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfEdYVqUUN3ME2zO{41ODJ5IN88US=> MXfTRW5ITVJ?
SF268 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HNe2lEPTB;M{iuN|Q{OyEQvF2= NHr2NppUSU6JRWK=
HGC-27 M4HzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTN6LkO3NVEh|ryP NUHaPZAzW0GQR1XS
DOHH-2 NV76UZZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojiTWM2OD1|OD63NVU5KM7:TR?= NHPLTG5USU6JRWK=
KE-37 NEXTWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN6Lkm4Nlgh|ryP M2mxenNCVkeHUh?=
MOLT-13 NYOyUm9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\OeJlKSzVyPUO5MlI2ODJizszN NWm5SZNbW0GQR1XS
ES1 NGT0d5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HEdGlEPTB;M{muN|g2KM7:TR?= MUDTRW5ITVJ?
SK-OV-3 NXrOdmFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHrTWM2OD1|OT65OlQ{KM7:TR?= NGjtdZFUSU6JRWK=
SNU-449 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfjT4VlUUN3ME20NE4xPzZ2IN88US=> MmD0V2FPT0WU
KYSE-510 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRyLkGyPVUh|ryP MlvmV2FPT0WU
HL-60 NEPteIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTjclJuUUN3ME20NE46Pzh|IN88US=> MmDxV2FPT0WU
DJM-1 M3rrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRyLkm3PVkh|ryP M3zRRnNCVkeHUh?=
TGBC11TKB MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TmVWlEPTB;NEGuNFkzPiEQvF2= NF3lWmdUSU6JRWK=
U-2-OS M4DK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nuN2lEPTB;NEKuNlY1OSEQvF2= MnHqV2FPT0WU
NCI-H2030 NVG3bYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTR{LkSzOlgh|ryP NEPFblZUSU6JRWK=
LU-135 M2fxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjI[45MUUN3ME20Nk42PDR5IN88US=> M1jpbXNCVkeHUh?=
ZR-75-30 M2TVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v5OGlEPTB;NEOuNFQ6OyEQvF2= M1z5NHNCVkeHUh?=
GT3TKB M3vSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jYd2lEPTB;NEOuNlY4QSEQvF2= NXP4UlE5W0GQR1XS
RPMI-2650 NXL5V4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\uTWM2OD12Mz63PFE3KM7:TR?= MnjVV2FPT0WU
SAS Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH30TGhKSzVyPUSzMlk2OzRizszN MoL3V2FPT0WU
MDA-MB-231 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLUd2R6UUN3ME20N{46PjB7IN88US=> MV3TRW5ITVJ?
JVM-3 M2jySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vCR2lEPTB;NESuNFU{OyEQvF2= NH3uTI5USU6JRWK=
COLO-320-HSR Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;peWlEPTB;NESuOVY{OyEQvF2= NFPD[pNUSU6JRWK=
SNB75 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfzNY1YUUN3ME20OE43OTB3IN88US=> NFzlTHhUSU6JRWK=
NCI-H441 MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O0TGlEPTB;NESuPVMzQCEQvF2= NYnDUJdvW0GQR1XS
HCT-116 NYX1NXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n0[2lEPTB;NESuPVg3QCEQvF2= NVGwWGgxW0GQR1XS
NCI-H226 M1:1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HOmlEPTB;NEWuOlM3QCEQvF2= MV;TRW5ITVJ?
CAL-33 NUHRVVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLjTWM2OD12NT65NlE4KM7:TR?= NFu2UIJUSU6JRWK=
NCI-H1437 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO2W5ZKSzVyPUS2MlMzOSEQvF2= MXfTRW5ITVJ?
HCC1187 NEnlfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfwXmM{UUN3ME20Ok41OjV3IN88US=> MkWyV2FPT0WU
NUGC-3 M3nTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXjcJJKSzVyPUS2MlU4ODlizszN Mn\VV2FPT0WU
T98G NHLZN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHtU3p3UUN3ME20O{42PDdizszN M4fuVHNCVkeHUh?=
OVCAR-8 NHnWd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX5XldKSzVyPUS3MlY5OyEQvF2= MVXTRW5ITVJ?
LB2241-RCC NWrSOYFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTJW5R6UUN3ME20O{44OjdizszN MULTRW5ITVJ?
NCI-H358 M4nvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nBWmlEPTB;NEiuNVE2OiEQvF2= NE\a[m9USU6JRWK=
PANC-08-13 Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXLb29KSzVyPUS4MlE5PTNizszN MYjTRW5ITVJ?
KP-N-YN NGrQWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjhXXZKSzVyPUS4MlIyODJizszN NFj1NmdUSU6JRWK=
NCI-H1755 M4HDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjoZ2RpUUN3ME20PE4zPzJ4IN88US=> M3SzTXNCVkeHUh?=
NCI-N87 M4CxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTR6LkK5PVEh|ryP MmTBV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
+ Expand

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
+ Expand
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Formulation: Prepared in sterile fashion
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water slightly soluble or insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID